Molecular Partners (NASDAQ:MOLN) Releases Earnings Results, Misses Estimates By $0.14 EPS

Key Points

• Molecular Partners reported a quarterly earnings loss of ($0.67) per share, missing the consensus estimate of ($0.53) by ($0.14).
• During trading, Molecular Partners' stock increased by $0.55, reaching a price of $4.22, with trading volume surpassing its average volume of 6,418 shares.
• The company is developing therapeutic candidates, including MP0317, currently in Phase I clinical trials for cancer treatment.

Molecular Partners (NASDAQ:MOLN - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.14), Zacks reports.

Molecular Partners Stock Up 6.3%

MOLN stock traded up $0.23 during trading on Friday, hitting $3.83. The company had a trading volume of 4,139 shares, compared to its average volume of 4,219. The firm has a market capitalization of $154.43 million, a P/E ratio of -1.84 and a beta of 1.10. Molecular Partners has a 52-week low of $3.36 and a 52-week high of $7.60. The company has a 50 day simple moving average of $3.70 and a 200-day simple moving average of $3.97.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.